Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

nformation identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedSeptember 30,Nine Months Ended September 30,(In thousands, except per share data)2010200920102009(unaudited)(unaudited)Revenues:Collaborative research$  632$  1,650$  3,437$  8,042Subscription and license fees1494812181,246Total revenues7812,1313,6559,288Operating expenses:Research and development, including stock-based compensation

of $751, $733, $2,366 and $2,328, respectively20,08619,32061,41362,404General and administrative, including stock-based compensation

of $582, $547, $1,592 and $1,750, respectively4,9484,56815,53514,993Total operating expenses25,03423,88876,94877,397Loss from operations(24,253)(21,757)(73,293)(68,109)Gain on investments, net-1851411,008Interest income51103468669Interest expense(637)(785)(2,093)(2,180)Other expense, net(2,700)(516)(4,025)(2,037)Consolidated loss before taxes(27,539)(22,770)(78,802)(70,649)Income tax benefit2610226102Consolidated net loss(27,513)(22,668)(78,776)(70,547)Less: Net loss attributable to noncontrolling interest in Symphony Icon, Inc.-3,526-9,772Net loss attributable to Lexicon Pharmaceuticals, Inc.$  (27,513)$  (19,142)$  (78,776)$  (60,775)Net loss  attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted$   (0.08)$  (0.14)$  (0.27)$  (0.44)Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc.  per common share, basic and diluted337,404137,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics ... company announces that the Company,s lead antibody, HuMab 5B1, ... five separate presentations during the upcoming World Molecular Imaging ... September 2-5, 2015. Researchers from the Department of ... present results on the use of MabVax,s lead antibody ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.17 billion by 2018 ... The near future will bring Biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.20 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Israel Biomedical Sensors Market - Growth, Trends ... The Israel Biomedical Sensors market is estimated ... 3.73% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Mexico Biomedical Sensors Market Report 2015-2020 2Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2
... November 2007, BARCELONA, Spain, October 9 ... 332 patients,with Overactive Bladder (OAB) and has been ... Spain, The Netherlands, Czech Republic, Hungary,Poland, Russia, South ... report the results of this trial during November. ...
... PARI Respiratory Equipment,s,breath-enhanced nebulizer, the PARI LC ... new COPD medication, Perforomist Inhalation Solution,that launched ... of Mylan Inc.,(NYSE: MYL ). ... for,long-term, twice-daily maintenance treatment of bronchoconstriction for,emphysema ...
... Solution, to Orthopedic Imaging, PARIS and ATLANTA, Oct. ... 510k clearance from the Food and Drug Administration,(FDA) to ... United States for 2D,imaging use. EOS 2D|3D technology ... images to be obtained with a low dose of ...
Cached Biology Technology:SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 4FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 2FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 3FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 4
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... Mass. The Center for Wireless Information Network Studies ... three-year, $1.2 million award from the National Institute of ... of the propagation of radio waves around and through ... electrical and computer engineering and director of CWINS, the ...
... 2010) Moffitt Cancer Center and Proteacel LLC announced today ... has acquired the exclusive rights to the PORE technology for ... the instructions that build cells. Defects in these genes cause ... genes work and their involvement in a disease process, researchers ...
... CORVALLIS, Ore. Fungi have significant potential for "horizontal" gene ... that allow bacteria to evolve so quickly, become resistant to ... be published Thursday in the journal Nature , suggests ... of their genomes and become infectious to plants and possibly ...
Cached Biology News:WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 2WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 3Moffitt Cancer Center signs licensing agreement with Proteacel, LLC 2Fungi can change quickly, pass along infectious ability 2
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
... Plus Array CGH Genomic Labeling Systems are ... labeling of genomic DNA samples for array-based ... indirect and direct labeling formats, the BioPrime ... a flexible solution to your genomic labeling ...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
Biology Products: